ClinicalTrials.gg
Not yet recruitingNCT07611786Updated Oct 14, 2026

Development of Healthcare Transition for Patients With Congenital Adrenal Hyperplasia

An observational study in Congenital Adrenal Hyperplasia, sponsored by University of Alabama at Birmingham. Not yet recruiting at 1 site in United States. Open to participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by University of Alabama at Birmingham · Observational

How we know

Updated Oct 14, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Adrenal Hyperplasia, Congenital with a site in United States — 10 open to participants now, 14 under way, 4 of them phase 3. Adrenal Hyperplasia, Congenital · United States.

Planned enrollment
9th of 11
40 · median 65
Started
2027
the only one that year
Observational
11 of 50
2 open now
Primary completion
2028-12
later than 7 of 12 live
Registered
50th of 50
by date

Among the 50 studies in Adrenal Hyperplasia, Congenital with a site in United States, this one is the 9th largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2027, is one of 11 observational ones, reaches primary completion later than 7 of the 12 other live ones, and was the 50th registered.

Adrenal Hyperplasia, Congenital

102 studies on the registry are indexed under Adrenal Hyperplasia, Congenital; 29 are open to participants now.

Browse Adrenal Hyperplasia, Congenital studies →

Open to participants now

10 of the 50 studies in Adrenal Hyperplasia, Congenital with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Adrenal Hyperplasia, Congenital studies recruiting now, 10 (50%) set no upper age limit and 9 (45%) stop at 75 or younger; 7 take children under 18; none take healthy volunteers.

This study: 16 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Adrenal Hyperplasia, Congenital with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to implement and evaluate the feasibility and acceptability of a structured healthcare transition program for adolescents and young adults with congenital adrenal hyperplasia (CAH). The study will also examine preliminary effects of the program on transition readiness, disease-specific self-management knowledge, emergency preparedness, continuity of endocrine care, and health-related quality of life as participants transition from pediatric to adult healthcare services.

Read the detailed description

Study Purpose and Rationale

Congenital adrenal hyperplasia (CAH) is a complex, lifelong endocrine disorder that requires continuous glucocorticoid replacement, stress-dosing during illness, and ongoing monitoring for metabolic, reproductive, and adrenal complications. Adolescents and young adults face substantial challenges maintaining these self-management responsibilities during the transition from pediatric to adult care, a period consistently associated with decreased adherence, reduced clinic attendance, lapses in emergency preparedness, and preventable adrenal crises. Despite these risks, there are currently no structured, evidence-informed transition programs tailored specifically to the needs of individuals with CAH.

The purpose of this study is to evaluate the feasibility, acceptability, and preliminary impact of implementing the Comprehensive Adolescent Healthcare Transition (CAH-T) program for adolescents and young adults with CAH. By combining structured education, readiness assessment, emergency preparedness training, and coordinated transfer to adult endocrinology, this mixed-methods pilot aims to strengthen self-management skills, improve continuity of care, and reduce acute health events. Findings will inform refinement of the CAH-T model and provide essential pilot data needed to support future multi-site implementation.

Objectives and Hypotheses

The overall objective of this mixed-methods feasibility study is to evaluate the implementation and preliminary effectiveness of the Comprehensive Adolescent Healthcare Transition (CAH-T) program for adolescents and young adults with congenital adrenal hyperplasia (CAH). The study aims to determine whether the intervention can be feasibly delivered in a pediatric endocrine clinic, is acceptable to patients and caregivers, and produces early improvements in transition-related outcomes.

The investigators hypothesize that.

  1. The CAH-T program will be feasible to implement, with recruitment, retention, and curriculum completion meeting predefined benchmarks.
  2. Participants and caregivers will rate the program as satisfactory.
  3. Participation in CAH-T will lead to improvements in transition readiness, CAH-specific knowledge, emergency preparedness, and successful linkage to adult endocrinology care, while supporting stable health-related quality of life.

Study Design Overview This is a prospective, single-center, single-arm, mixed-methods feasibility and implementation study conducted over 24 months. Adolescents and young adults aged 16-20 years with a diagnosis of CAH, along with one of their caregivers, will participate in a structured transition curriculum integrated into routine endocrine visits. Quantitative measures of readiness, knowledge, quality of life, and emergency preparedness will be collected at baseline, post-intervention, and at 12-month follow-up. Semi-structured interviews with adolescents, caregivers, and providers will be used to contextualize quantitative findings and identify implementation barriers and facilitators.

Population and Sample Size Summary

The study will enroll approximately 15 adolescents and young adults with CAH (ages 16 years and older) and one caregiver per participant from the Children's Hospital of Alabama pediatric endocrinology clinic. This sample size is appropriate for feasibility pilot work in a rare disease population and will provide sufficient data to estimate feasibility metrics, evaluate acceptability, and generate preliminary effect-size estimates for future multi-site trials.

Primary and Secondary Outcomes

Primary Outcomes

  • Feasibility:

    • Recruitment ≥75% of eligible participants within the 24 months of the study timeline
    • Retention ≥80% at 6- and 12-month follow-up
    • Curriculum completion ≥70% for participants enrolled by their 12-month follow-up endpoint.
  • Acceptability: ≥80% of participants and caregivers rate the program "satisfied/very satisfied" at their 12-month follow-up

Secondary Outcomes

  • Transition Readiness: ≥10% improvement in STARx/STARx-P scores at the 12 month follow-up compared to a baseline score.
  • CAH-Specific Knowledge: ≥10% improvement in CAHKAQ scores at the 12 month follow-up compared to a baseline score.
  • Emergency Preparedness:

    • ≥70% medical alert use
    • ≥90% possession of injectable hydrocortisone
    • ≥80% updated adrenal insufficiency action plan in the chart
  • Health-Related Quality of Life: ≤10% change in CAHQL scores over 12 months
  • Transfer Outcomes: ≥80% of eligible participants attend at least one adult endocrinology visit within 6 months post-transfer
  • Acute Care Utilization: Stable or reduced emergency/urgent care visits pre- vs. post-intervention

Brief Procedures Summary

Participants will complete a baseline assessment including demographics, CAH knowledge (CAHKAQ),9 transition readiness (STARx/STARx-P),10-12 emergency preparedness, and quality-of-life measures (CAHQL).13 They will then participate in two CAH-T curriculum14 visits embedded in routine endocrine appointments. Age-eligible participants (over 18 years old) will be transferred to adult care following completion of the curriculum and monitored for completion of an adult endocrinology visit. All participants will complete a 12-month follow-up assessment, and emergency care utilization will be recorded for the year preceding enrollment and for the year following intervention completion. Semi-structured interviews will be conducted with adolescents, caregivers, and providers after the program's implementation to explore perceptions of the program's feasibility and acceptability.

Significance / expected impact This study aims to address a significant gap in endocrine transitional care by piloting the first structured, CAH-specific transition program at a U.S. pediatric center. The implementation of CAH-T is expected to improve self-management skills, enhance preparedness for adrenal crises, support a stable quality of life, and increase successful connection to adult endocrinology care. Findings will generate foundational evidence needed to refine the intervention and support future multi-site trials aimed at establishing best practices for transition in rare endocrine disorders.

03

Conditions studied

  • Congenital Adrenal Hyperplasia

Keywords

  • congenital adrenal hyperplasia
  • healthcare transition
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

This population will be recruited from our pediatric endocrinology clinic as available.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

YA Participants

  • Diagnosis of congenital adrenal hyperplasia (any subtype or severity)
  • Age ≥16 years
  • Active follow-up within the pediatric endocrinology clinic
  • English-speaking
  • Cognitively able to complete questionnaires with or without assistance
  • Anticipated ability to participate in CAH-T visits during the study period Caregiver Participants
  • Parent, guardian, or primary support person of an enrolled AYA participant Provider Participants
  • Pediatric endocrinologists, nurse practitioners, or transition-related clinical staff involved in CAH care for at least 6 months

Exclusion criteria

Exclusion Criteria:

  • Significant cognitive impairment precluding participation
  • Inability to complete study procedures
  • Inability to provide /assent
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • adolescent and young adult with congenital adrenal hyperplasia

    Other: exposure to healthcare transition protocol

  • guardian/caregiver of adolescent/young adult with congenital adrenal hyperplasia

    Other: exposure to healthcare transition protocol

  • clinical provider of patients with congenital adrenal hyperplasia

    Other: exposure to healthcare transition protocol

Interventions

  • Otherexposure to healthcare transition protocol

    CAH-T Curriculum Visits CAH-T Visit 1 (V1) CAH-T Visit 1 will occur approximately 3 months after enrollment and will include: * Review of CAH disease management * Stress dosing education * Emergency hydrocortisone instruction * Medical alert education * Teach-back demonstration of emergency injection technique * Discussion of adherence, mental health, fertility/sexual health, bone health, and cardiometabolic health * Introduction to healthcare transition concepts * Development of individualized transition goals For participants aged ≥18 years: * Identification of adult endocrinology provider * Development of transfer plan * Medical summary review/update Relevant educational materials are included in attachments. CAH-T Visit 2 (V2) CAH-T Visit 2 will occur approximately 6 months after enrollment and will include: * Reinforcement of CAH self-management concepts * Review of emergency preparedness * Review of transfer readiness * Finalization of transfer planning

06

What researchers measure

Primary outcomes

  1. assessment of CAH knowledge

    Brief survey of CAH knowledge with Congenital adrenal hyperplasia knowledge questionnaire looking at the treatment of the condition and the mechanism of congenital adrenal hyperplasia. Minimum score 0; Maximum score 44; with 0 indicating lack of knowledge of CAH

    Time frame: at baseline, 6 months, and 12 month after initiation of healthcare transition readiness

  2. Self-Management and Transition to Adulthood with Rx (Self-Management and Transition to Adulthood with Rx-parent) questionnaire regarding transtion readiness

    This questionnaire assesses patient's readiness for movement to adult healthcare. minimum score of 0, maximum score of 90. 0 indicating patient is not ready for movement to the adult healthcare system.

    Time frame: at baseline, 6 months and after 12 month visit

  3. Change in quality of life for patients with CAH

    assessment of CAH quality of life with questionnaire (CAHQL). Scale from 0-100 with increasing scale indicating a higher quality of life.

    Time frame: at baseline, and 6 and 12 month follow-up

Secondary outcomes

  1. number of participants that receive the emergency preparedness checklist

    checklist to understand patient understanding of preparing for adrenal crisis

    Time frame: baseline, 6 months, and 12 months after initiation of transition protocol

  2. number of visits a participant requires for acute care

    review of patient's use of acute care for adrenal insufficiency. We will count the number of times a participant has to use an ER or urgent care clinic within a 6 month time frame (inquiring at baseline, 6 month, and 12 month visit)

    Time frame: baseline, 6 months and 12 months after initiation of healthcare transition protocol

  3. Assess satisfaction and experience survey

    assessment of satisfaction and experience survey. 5 question survey of Likert scale ranging 1-5 with 5 indicating very satisfied.

    Time frame: after completion of 12 month visit of health care transition protocol

  4. themes regarding CAH healthcare transition

    themes from focus groups from adolescents and young adults with CAH guardians/caregivers, and providers

    Time frame: up to 24 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jan 2027; primary completion for Dec 2028, 23 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: start Oct 2026 → Jan 2027, primary completion Oct 2028 → Dec 2028 and completion Oct 2029 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2026
First posted
May 28, 2026
StartEst.
Jan 2027was Oct 2026
Primary completionEst.
Dec 2028was Oct 2028
CompletionEst.
Dec 2029was Oct 2029
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 2026→Jan 2027
Oct 14, 2026
Primary completion
Oct 2028→Dec 2028
Oct 14, 2026
Study completion
Oct 2029→Dec 2029
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Start date Oct 2026→Jan 2027
    Primary completion Oct 2028→Dec 2028
    Study completion Oct 2029→Dec 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07611786
Responsible party
Christy Foster (primary investigator, University of Alabama at Birmingham) — Principal investigator
First posted
May 28, 2026
Start date
Jan 2027 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Oct 14, 2026

Study contacts

Christy Foster, MD
Contact
cafoster@uabmc.edu
205-638-9107
Leslie Pitts, PHD
Contact
lesliepitts@uab.edu
Christy Foster, MD
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion